Table 1 A list of active and completed immuno checkpoint inhibitor (ICI) clinical trials for various malignancies
Study name /ID | Immune checkpoint inhibitors (ICIs) | Conditions | Molecular Target | Interventions | Phase | Status | Study start date/first posted | Study completion date/last posted | Results posted |
|---|---|---|---|---|---|---|---|---|---|
NCT03313804 | Nivolumab, Atezolizumab or Pembrolizumab | Advanced Disease HNSCC | PD-1, PD-L1 | Radiation therapy and ICIs | Phase 2 | Recruiting | October 26, 2017 | February 2025 | No |
NCT05329532 | Pembrolizumab | HNSCC, Breast, ovarian or renal cancer | PD-1 | Modi-1/Modi-1v, Pembrolizumab | Phase 1/2 | Recruiting | April 7, 2022 | June 30, 2026 | No |
NCT03544723 | Nivolumab, Atezolizumab, Pembrolizumab, or durvalumab | Recurrent or Metastatic HNSCC and other Tumors Approved for Anti-PD-1 or Anti-PD-L1 Therapy (melanoma, renal, gatric, cervical cancer etc.…) | PD-1, PD-L1 | Ad-p53 and Immunotherapy | Phase 2 | Recruiting | October 1, 2018 | December 31, 2022 | No |
NCT03050060 | Nivolumab, Atezolizumab or Pembrolizumab | Recurrent NSCLC, advanced Melanoma, or Kidney Cancer | PI3K, PD-1, PD-L1 | Hypofractionated Image Guided Radiotherapy With Concurrent Nelfinavir and ICIs | Phase 2 | Terminated | February 10, 2017 | June 22, 2022 | No |
NCT03014648 | Atezolizumab | Advanced NSCLC previously treated with either nivolumab or pembrolizumab | PD-L1 | ICIs | Phase 2 | Terminated | July 18, 2017 | March 31, 2022 | No |
NCT03841110 | Nivolumab, pembrolizumab or atezolizumab | Advanced solid tumors (NSCLC, Breast, Gastric, pancreatic etc.…) | PD-1, PD-L1 | FT500 as Monotherapy and in Combination With ICIs | Phase 1 | Active not recruiting | February 15, 2019 | November 17, 2022 | No |
NCT03693014 | Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab | Lung, melanoma, bladder, renal and Head and Neck cancer | CTLA4, PD-1, PD-L1 | Stereotactic body radiation therapy (SBRT) and ICIs | Phase 2 | Recruiting | October 2, 2018 | November 18, 2022 | No |
NCT03774732 | Pembrolizumab | NSCLC, NSCLC metastatic | PD-1 | ICI and Chemotherapy With Concurrent Irradiation | Phase 3 | Recruiting | December 13, 2018 | July 28, 2022 | No |
NCT04902040 | Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, Plinabulin and Radiation Therapy | Advanced Melanoma, Advanced Bladder Carcinoma, Advanced Malignant Solid Neoplasm | PD-1, PD-L1 | Plinabulin with ICIs and Concurrent Irradiation | Phase 1/2 | Recruiting | April 14, 2021 | June 1, 2025 | No |
NCT03115801 | Atezolizumab, Nivolumab, Pembrolizumab | Metastatic Genitourinary Cancers | PD-1, PD-L1 | Immunotherapy Plus Radiotherapy | Phase 2 | Terminated (lack of accrual) | April 14, 2017 | September 22, 2021 | Si |
NCT05287464 | Pembrolizumab | Metastatic Renal Cell Carcinoma (mRCC) | PD-1, VEGF | pembrolizumab plus axitinib | ND | Recruiting | March 18, 2022 | September 2, 2022 | No |
NCT05607953 | Pembrolizumab | Locally Advanced Pancreatic Ductal Adenocarcinoma | PD-1, TLR9 | pembrolizumab plus SD-101 | Phase 1 | Recruiting | November 7, 2022 | November 23, 2022 | No |
NCT03727880 | Pembrolizumab | Resectable Pancreatic Ductal Adenocarcinoma | PD-1, FAK | pembrolizumab plus defactinib | Phase 2 | Recruiting | November 1, 2018 | March 23, 2022 | No |
NCT03979066 | Atezolizumab | Resectable Pancreatic Ductal Adenocarcinoma | PD-L1, HA | Atezolizumab and PEGPH20 | Phase 2 | Terminated | June 7, 2019 | December 23, 2020 | Si |
NCT04666740 | Pembrolizumab | Metastatic Pancreatic Ductal Adenocarcinoma | PD-1, PARP | Pembrolizumab and Olaparib | Phase 2 | Recruiting | December 14, 2020 | November 14, 2022 | No |
NCT05273554 | Pembrolizumab | Advanced Pancreatic Ductal Adenocarcinoma | Pembrolizumab and VEGFR1/2/3 | Pembrolizumab Plus Lenvatinib | Phase 1 | Recruiting | March 10, 2022 | October 14, 2022 | No |
NCT03952325 | Pembrolizumab, Atezolizumab or Nivolumab | Triple-Negative MBC | PD-1, PD-L1, Tubulin | CPIs and Tesetaxel | Phase 2 | Terminated,tesetaxel discontinued | May 16, 2019 | July 30, 2021 | No |
NCT04638751 | Pembrolizumab, Nivolumab, Ipilimumab, Atezolizumab, Durvalumab, Avelumab, Cemiplimab | TNBC, NSCLC, CRC, pancreatic cancer | PD-1, PD-L1 | Immunotherapy and Chemotherapeutic Agent | Observational | Recruiting | November 20, 2020 | December 2024 | No |
NCT03406858 | Pembrolizumab | Castration-Resistant Prostate Carcinoma | PD-1, HER2 | Pembrolizumab, HER2Bi-Armed Activated T Cells | Phase 2 | Active, not recruiting | January 23, 2018 | November 15, 2022 | No |
NCT03572478 | Nivolumab | Prostate or Endometrial Cancer | PD-1, PARP | Nivolumab, rucaparib | Phase 1/2 | It was terminated due to lack of efficacy | June 28, 2018 | March 9, 2021 | Si |
NCT02423928 | Ipilimumab | Prostate Cancer | CTLA4, DNA | Dendritic cell based cryoimmunotherapy, Cyclophosphamide, Ipilimumab | Phase 1 | Completed | April 22, 2015 | October 25, 2019 | No |
NCT02601014 | Ipilimumab and Nivolumab | Metastatic Hormone-Resistant Prostate Cancer Expressing androgen receptor-variant-7 (AR-V7) | CTLA4, PD-1, Androgen hormone | Ipilimumab, Nivolumab, Enzalutamide | Phase 2 | Completed | November 10, 2015 | February 3, 2022 | Oncotarget. 2018 Jun 19;9(47):28,561–28,571. Prostate . 2021 May;81(6):326–338 |
NCT03673787 | Atezolizumab | Solid Tumor, Glioblastoma Multiforme and Prostate Cancer Metastatic with PI3K hyperactivation | PD-L1, AKT1 | Ipatasertib, Atezolizumab | Phase 1/2 | Recruiting | September 17, 2018 | November 2023 | No |
NCT02113657 | Ipilimumab | Metastatic Castration-Resistant Prostate Cancer | CTLA4 | Ipilimumab | Early Phase 1 | Completed | April 14, 2014 | January 10, 2020 | No |
NCT03047473 | Avelumab | Newly Diagnosed Glioblastoma Multiforme | PD-L1 | Avelumab | Phase 2 | Completed | February 9, 2017 | July 21, 2022 | No |
NCT03422094 | Nivolumab, Ipilimumab | Newly Diagnosed, Unmethylated Glioblastoma | PD-1, CTLA4 | poly-ICLC (NeoVax), Nivolumab, Ipilimumab | Phase 1 | Terminated (Manufacturer changed focus to cell therapy) | February 5, 2018 | October 27, 2021 | No |
NCT02550249 | Nivolumab | Glioblastoma | PD-1 | Neoadjuvant Nivolumab | Phase 2 | Completed | September 15, 2015 | April 11, 2017 | No |
NCT03367715 | Nivolumab, Ipilimumab | Newly Diagnosed, MGMT Unmethylated Glioblastom | PD-1, CTLA4 | Nivolumab, Ipilimumab, short-course of Radiation Therapy (RT) | Phase 2 | Completed | December 11, 2017 | July 1, 2022 | Si |
NCT03707457 | Nivolumab, Ipilimumab | First Recurrence of Glioblastoma | PD-1, GITR, IDO1, CTLA4 | Nivolumab and Anti-GITR Monoclonal Antibody MK-4166. IDO1 inhibitor and INCB024360 Ipilimumab | Phase 1 | Terminated | October 16, 2018 | July 2, 2020 | No |
NCT02617589 | Nivolumab | Newly-diagnosed Glioblastoma | PD-1, DNA | Nivolumab, Temozolomide, Radiotherapy | Phase 3 | Completed | December 1, 2015 | March 29, 2022 | Neuro Oncol. 2020 Sep; 22(9): 1233–1234 |